Nkarta, Inc. Debt Securities, Available-for-sale
Nkarta, Inc. (NKTX) had Debt Securities, Available-for-sale of $215.48 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-10
- 2026-06-30: Debt Securities, Available-for-sale $215.48M.
- 2026-03-31: Debt Securities, Available-for-sale $236.64M.
- 2025-12-31: Debt Securities, Available-for-sale $252.75M.
- 2025-09-30: Debt Securities, Available-for-sale $313.48M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2026-06-30 | $215.48M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $236.64M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $252.75M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $313.48M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $330.60M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $348.42M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $349.87M 10-K · filed 2026-03-25 |
| 2024-09-30 | $402.30M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $423.34M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $196.92M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $217.15M 10-K · filed 2025-03-26 |
| 2023-09-30 | $237.35M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $270.36M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $275.69M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $314.65M 10-K · filed 2024-03-21 |
| 2022-09-30 | $352.70M 10-Q · filed 2022-11-09 |
| 2021-12-31 | $177.27M 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |